ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Vaxxinity Inc

Vaxxinity Inc (VAXX)

0.1111
0.00
( 0.00% )
Updated: 19:00:00

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.1111
Bid
0.1068
Ask
0.107
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
0.1111
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
126,747,684
Dividend Yield
-
PE Ratio
-0.24
Earnings Per Share (EPS)
-0.45
Revenue
-
Net Profit
-56.93M

About Vaxxinity Inc

Vaxxinity Inc is engaged in the development and commercialization of prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its pipeline primarily consists of five programs focused on chronic disease, particul... Vaxxinity Inc is engaged in the development and commercialization of prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its pipeline primarily consists of five programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-

VAXX Latest News

Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine

UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living. Data demonstrates...

Vaxxinity Issues Shareholder Letter

CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (β€œVaxxinity”, β€œwe”,Β β€œus” or the β€œCompany”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (β€œVaxxinity”, β€œwe”,Β β€œus” or the β€œCompany”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

CAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present...

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported...

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PDβ„’ 2024

LISBON, Portugal, March 07, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ: VAXX), a U.S. company pioneering the development of a new class of medicines, announced positive clinical data from...

Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BTCTBTC Digital Ltd
$ 11.05
(338.49%)
111.8M
MULNMullen Automotive Inc
$ 3.06
(78.95%)
44.36M
PAMTPAMT Corporation
 21.75
(72.48%)
47.1k
AGFYAgrify Corporation
$ 7.86
(62.73%)
903.37k
LGMKLogicMark Inc
$ 0.201
(51.13%)
515.05M
NGNENeurogene Inc
$ 38.11
(-46.72%)
1.2M
STIMNeuronetics Inc
$ 0.6552
(-40.44%)
6.19M
ACABAtlantic Coastal Acquisition Corporation II
$ 6.60
(-39.45%)
17.78k
RAILFreightCar America Inc
$ 9.931
(-36.79%)
2.06M
RMTIRockwell Medical Inc
$ 2.94
(-36.77%)
5.23M
CEROCERo Therapeutics Holdings Inc
$ 0.2516
(28.37%)
658.99M
LGMKLogicMark Inc
$ 0.201
(51.13%)
517.6M
LIFWMSP Recovery Inc
$ 0.1195
(-5.68%)
164.2M
NVDANVIDIA Corporation
$ 148.045
(1.92%)
143.58M
ELABElevai Labs Inc
$ 0.0188
(-2.59%)
125.76M

VAXX Discussion

View Posts
PonkenPlonken PonkenPlonken 4 months ago
i feel sorry for Mei Mei and the team. The timing of the IPO and the small cap biotech bearmarket hurt them badly. Wrong place wrong time.
Lets see, i dont think you can hold Mei Mei down.
👍️ 1
TrendTrade2016 TrendTrade2016 5 months ago
VAXX monster move
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 5 months ago
Delist play
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 5 months ago
VAXX blowing up
πŸ‘οΈ0
glenn1919 glenn1919 6 months ago
VAXX................................https://stockcharts.com/h-sc/ui?s=VAXX&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Renee Renee 6 months ago
VAXX delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions
πŸ‘οΈ0
stock1ace1 stock1ace1 6 months ago
Why? Delisting ..
πŸ‘οΈ0
Triple nickle Triple nickle 6 months ago
Load em up
👍️ 1
Awl416 Awl416 6 months ago
No clue why
πŸ‘οΈ0
Awl416 Awl416 6 months ago
Pop
πŸ‘οΈ0
Tom turtles Tom turtles 7 months ago
Lol...bye bye VAXX...good riddance
πŸ‘οΈ0
Awl416 Awl416 7 months ago
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
πŸ‘οΈ0
Awl416 Awl416 8 months ago
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
πŸ‘οΈ0
81vette 81vette 8 months ago
not off hand,look on fda site,let us know,thanks!!!
πŸ‘οΈ0
Monroe1 Monroe1 8 months ago
Any idea when the Phase 3 trial should finish?
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
VAXX new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
VAXX under $2
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
VAXX new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
VAXX new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
VAXX under $2
πŸ‘οΈ0
81vette 81vette 2 years ago
new and effective covid booster news coming is the thought,15 days of charting up and institutions loading while crickets are chirping
πŸ‘οΈ0
81vette 81vette 2 years ago
https://ih.advfn.com/stock-market/NASDAQ/vaxxinity-VAXX/stock-news/89692734/vaxxinity-announces-positive-topline-pivotal-phase
πŸ‘οΈ0
81vette 81vette 2 years ago
10Xs ave vol,blowing up scanners on this low float
πŸ‘οΈ0
81vette 81vette 2 years ago
1M short ,squeeze babe !!! could be big news enroute with institutional buying like this
πŸ‘οΈ0
81vette 81vette 2 years ago
biggest ever institution loading> Bank Of America 3.22 mm +3.20 mm +20179.3%
Vanguard 1.53 mm +1.48 mm +2676.7%
Marshall Wace 620.46 k +620.46 k NEW
Element Capital Management 376.89 k +376.89 k NEW
Creative Planning 277.52 k +277.52 k NEW
Renaissance Technologies 262.40 k +262.40 k NEW
Millennium Management 213.62 k +213.62 k NEW
Prime Movers Lab 17.85 mm -179.00 k -1.0%
Two Sigma Investments 128.52 k +128.52 k NEW
Ghisallo Capital Management 100.00 k +100.00 k NEW
πŸ‘οΈ0
81vette 81vette 2 years ago
3Xs ave vol.,no news,dbl bottom,47% insider owned
πŸ‘οΈ0
bandit007 bandit007 2 years ago
Loaded the crap out of this today
πŸ‘οΈ0
bandit007 bandit007 2 years ago
Sexy looking bottom chart. Starting to move up now. $VAXX
πŸ‘οΈ0
bandit007 bandit007 2 years ago
Stop losses below 3 got taken out. Should start moving up now
πŸ‘οΈ0
bandit007 bandit007 2 years ago
Took a few down here
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
and on low volume
πŸ‘οΈ0
bandit007 bandit007 2 years ago
Got vaxx? :)
πŸ‘οΈ0
bandit007 bandit007 2 years ago
Breaking out
πŸ‘οΈ0
bandit007 bandit007 2 years ago
On watch again
πŸ‘οΈ0
bandit007 bandit007 3 years ago
I only hold a small position speculating here. Could be either gold or fool’s gold. Could pay off well if it ends up being the real deal. GL
πŸ‘οΈ0
Deano361 Deano361 3 years ago
Trading nicely today now and not spikey
πŸ‘οΈ0
Deano361 Deano361 3 years ago
I'm in this one now. Can't figure out if real or not. Some guy on Twits board claims it's a Nancy Pelosi fraud lol! I have no idea but if they truly figure out a Alz vaccine this will be like Moderna in the 100s
πŸ‘οΈ0
bandit007 bandit007 3 years ago
Nice bounce back from the morning dip. $VAXX
πŸ‘οΈ0
bandit007 bandit007 3 years ago
VAXX hod close?
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
Nice trade! Maybe some news coming next week.
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
5.74 vol HALT down

only P1 news

I learned from crude to be careful with P1's I got burned on one that I lost $80,000

#HardLesson
πŸ‘οΈ0
Awl416 Awl416 3 years ago
Impressive
πŸ‘οΈ0
TheFinalCD TheFinalCD 3 years ago
GOT VAXX?
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
VAXX halted > Nasdaq circuit breaker.

πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
Vaxxinity Shares Surge More Than 40% in Trading Debut After IPO VAXX
12:02 pm ET November 11, 2021 (Dow Jones)
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
Vaxxinity, Inc. is a biotechnology company. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) enables a new class of therapeutics that will improve the access to treatments for a range of indications. Its Vaxxine Platform is designed to connect the immune system to convert the body into its own drug factory, stimulating the production of antibodies with a therapeutic or protective effect. Its technology uses synthetic peptides to mimic and optimally combine biological epitopes in order to selectively activate the immune system, producing antibodies against only the desired targets, including self-antigens, making possible the safe and effective treatment of chronic diseases by vaccines. The modular and synthetic nature of its Vaxxine Platform provides significant in candidate development and has generated multiple product candidates that it is designing for many chronic diseases.
πŸ‘οΈ0